and present antigens to T-lymphocytes, which subsequently target malignant cells [1] . Dendritic cells (DC) are the key APC population for initiating and coordinating antitumor responses [1, 2] . Despite the potential for tumor control, the immune system often fails. Numerous mechanisms, including deletion of tumor-specific cytotoxic T-lymphocytes [3] and recruitment of regulatory T-lymphocytes [4] and inhibitory cell types [5] , have been implicated in this failure. It has also been suggested that a tumor's incapacity to recruit DC significantly contributes to immune evasion [6 -8] .
More recently, the suppressive effects of tumors on DC maturation and differentiation have been reported to play a crucial role in the systemic failure of the host to mount an effective antitumor response [9 -11] . Several tumor-derived factors [vascular endothelial growth factor (VEGF), interleukin (IL) 6, macrophage colony-stimulating factor (M-CSF), gangliosides, prostanoids, and polyamines] affect DC differentiation from progenitors, both in vitro and in vivo [12 -18] . This is consistent with the fact that reduced DC counts are frequently found in the peripheral blood of cancer patients [13, 16, 19, 20] . A review of the effects of tumor-derived factors on DC was recently compiled [21] .
In spite of this evidence, only a few studies have directly assessed the functional status of DC populations circulating in vivo in patients with cancer [8, 13, 16, 22] . Circulating blood DC can be identified as mononuclear cells expressing major histocompatibility complex (MHC) II molecules (HLA-DR) but lacking common lineage markers (Lin) such as CD3, CD14, CD19, CD20, CD56, and CD34 [23] . This blood DC compartment (Lin À HLA-DR + cells) includes two different subsets that are discernible into myeloid or plasmacytoid DC based on their reciprocal expression of CD11c (a-integrin) and CD123 (IL-3 receptor a) [24] . The aim of this study was to assess the blood DC compartment in patients with cancer to ascertain whether alterations in DC subset distribution could correlate with tumor progression. For this purpose, we analyzed a large cohort of patients with different types of cancer (including breast cancer, prostate cancer, and malignant glioma) at various stages of disease. A 12-week chronological monitoring was also performed in patients with malignant glioma to relate any changes in the composition of the blood DC compartment with tumor recurrence in individual patients. Our results indicate that, in contrast to healthy donors, patients with cancer demonstrate a marked alteration in the distribution of myeloid (CD11c Notably, accumulation of these immature cells with poor APC function correlates with disease status and tumor growth. These findings may prove to be relevant in understanding DC pathophysiology in cancer progression.
Materials and Methods

Patients and Donors
A total of 120 female patients (43 -80 years of age) with histologically confirmed breast adenocarcinoma were enrolled in the study. any tumor size/node involvement with distant metastases to other organs [M 1 ]). All patients were newly diagnosed, except for those with advanced disease who presented with recurrence after a disease-free interval and had no prior therapy for at least 6 months. Staging was performed in accordance with International Union Against Cancer: TNM Classification of Malignant Tumors [25] . In addition, 10 male patients (68 -80 years of age) with histologically confirmed prostate cancer were enrolled in the study. All patients had hormone-refractory tumors with elevated and rising prostatespecific antigen (PSA) levels on at least two consecutive occasions, ranging from 11 to 890 ng/ml, in the presence of castrate serum testosterone levels. Although the International Union Against Cancer system does not have a clear category for the first seven patients who had consistently rising serum PSA values (all > 4 ng/ml) in the absence of bone or soft tissue metastases, the conditions of the remaining three patients were classified as stage IV ([TNM 1 ]: any tumor size/ node involvement with distant metastases to other organs [M 1 ]). Of these, one patient had multiple soft tissue secondary deposits and two had bone metastases. Three patients had some of their soft tissue tumor materials harvested as a source of antigens in a vaccine study. In addition, a total of six patients (three females and three males, 26 -68 years of age) with newly diagnosed supratentorial high-grade malignant glioma (grade IV) were enrolled in the study. Grading was performed in accordance with the World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Nervous System [26] . For the follow-up study, glioma patients who were initially treated and underwent complete macroscopic resection were monitored. Blood samples were collected starting at 4 weeks and then at 6, 8, and 12 (24) weeks after tumor resection. To assess tumor recurrence, each patient underwent computed tomography (CT) and/or magnetic resonance imaging (MRI) of the brain and comprehensive clinical examination at 4, 6, 8, and 12 (24) weeks postsurgery. According to uniform clinical protocols, two patients received symptomatic management with phenytoin and diazepam during the follow-up period. One patient received temozolamide and two underwent additional surgical excision of tumor recurrence after the follow-up period. Finally, 20 healthy donors (12 females and 8 males, 22 -73 years of age) volunteered for the study and served as controls. For phenotypic and cell sorting experiments, 50 or 350 ml of venous blood was collected into heparinized tubes and processed immediately. The research ethics committees of both clinical (Wesley Medical Centre, Royal Brisbane and Women Hospital and Mater Misericordiae Hospital) and scientific (Queensland Institute of Medical Research) institutions approved the study protocols.
Monoclonal Antibodies, Reagents, and Cytokines
The following monoclonal antibodies were used in this study: CD3, CD14, CD19, CD20, CD56, CD34, CD2, CD4, CD33, CD7, CD11c, HLA-DR, CD15, CD127, CD123, CD80, CD86, DC-SIGN, and IgG1, IgG2a, and IgG2b isotype controls from BD Pharmingen (BD Biosciences, San Jose, CA); CD62L, CD4, HLA-DR, CD40, CD83, CD19, and IgG1 isotype control from Beckman Coulter (Fullerton, CA); and BDCA-2, BDCA-3, BDCA-4, and CD1c from Miltenyi Biotech (Bergisch Gladbach, Germany). CD10, CD79a, CD11b, CD13, myeloperoxidase (MPO), CD41, CD61, CD235a, and CD71 (all from BD Biosciences) and SIgE, SIgn, and Cm (all from DakoCytomation, Fort Collins, CO) were kindly provided by Dr. Greg Bryson (Royal Brisbane Hospital, Brisbane, Australia). Fluorescein isothiocyanate (FITC) -, PE-, biotin-, APC-, or PE-Cy5-conjugated antibodies were used. For indirect staining with biotinylated antibodies, streptavidin APC (BD Biosciences) was used. For exclusion of dead cells, samples were stained with 7-amino-actinomycin D (7-AAD; BD Biosciences). Tetanus toxoid (TT) obtained from CSL (Melbourne, Victoria, Australia) was conjugated with FITC (FITC-TT) in 0.5 M bicarbonate buffer (pH 9.5) and dialyzed in phosphate-buffered saline (PBS) for 48 hours before use. Dialysis membranes (membra cell; Polylabo, Strasbourg, France) with a M w cutoff of under 10,000 to 14,000 were used. Sheep red blood cells were obtained from Equicell (Melbourne, Victoria, Australia). Complete media included RPMI 1640 supplemented with 10% fetal calf serum, penicillin (100 U/ml), streptomycin (100 mg/ml), L-glutamine (2 mM), HEPES (25 mM), and nonessential amino acids (all purchased from Gibco Life Technologies, Gaithersburg, MD). The combination of proinflammatory cytokines [27] consisted of IL-1b (10 ng/ml), IL-6 (10 ng/ml), and TNF-a (10 ng/ml) (all obtained from R&D Systems, Minneapolis, MN) plus prostaglandin E 2 (PGE 2 ; 1 mg/ml; Sigma, St. Louis, MO). The CpG oligodeoxynucleotide 2216 (CpG ODN; 3 mg/ml) [28] was acquired from Geneworks (Melbourne, Victoria, Australia). Lipopolysaccharide (LPS; 50 ng/ml) and double-stranded RNA (poly I:C; 50 mg/ml) [29] were purchased from Sigma.
Cell Purification and Microscopy
DC and DR + IC were purified from peripheral blood mononuclear cells (PBMC). Briefly, PBMC from patients with breast cancer were stained with lineage mixture (CD3, CD14, CD19, CD20 and CD56) and CD34 (all FITC), HLA-DR (PE), and CD11c (APC), and then indirectly stained with biotinylated CD123 followed by streptavidin (APC). CD34 was added to the lineage mixture (Lin) to exclude circulating hematopoietic stem cells. 
Statistical Analysis
Comparisons of samples for the establishment of statistical significance were determined by two-tailed Student's t test. Results were considered to be statistically significant when P < .05.
Results
Blood DC Subset Composition in Cancer
The blood DC compartment (Lin À HLA-DR + population) ( Figure 1A ) includes two different DC subsets that can be distinguished into myeloid and plasmacytoid lineages based on their reciprocal expression of CD11c and CD123 antigens [24] . Given that dissimilar alterations in the frequency of these subsets have been reported in patients with cancer [16, 20] , we set out to carefully analyze the CD11c + DC and CD123 + DC subset compositions of the blood DC compartment in a cohort of 34 patients with different types of solid tumors. We assessed patients with breast cancer (stage II; n = 18), malignant glioma (grade IV; n = 6), and hormonerefractory prostate cancer (n = 10). In addition, 11 agematched healthy donors served as controls ( Figure 1B) . In healthy donors, the proportion of CD11c + DC (46.6 ± 7.4%) and CD123 + DC (36.9 ± 6.6%) accounted for 83.5 ± 1.7% of the total blood DC compartment. In contrast, in patients with breast cancer, both DC subtypes accounted for 67.9 ± 3.1% (CD11c + DC: 46.0 ± 4.2% and CD123 + DC: 21.9 ± 2.8%); in malignant glioma, both DC subtypes accounted for 67.9 ± 3.6% (CD11c Interestingly, although this population represented only 16.4 ± 1.7% of the blood DC compartment in healthy donors, it represented a significantly larger proportion in patients with breast cancer (31.2 ± 3.1%), glioma (32.0 ± 3.6%), and prostate cancer (34.2 ± 3.9%; Figure 1C ). These results were further confirmed when a second cohort of 35 patients with breast cancer was assessed (CD11c 
Correlation with Tumor Burden
Given that our data demonstrated a larger increment in the proportion of DR + IC in patients with advanced breast cancer, we set out to assess whether numeric changes could correlate with status of disease. To test this, we estimated the absolute numbers of circulating DR + IC in the peripheral blood of 28 patients with breast cancer, and we subsequently analyzed their distribution according to the stage of disease (stage I, n = 10; stage II, n = 10; and stage IV, n = 8). We found that although the absolute numbers of DR + IC were comparable in healthy donors and early-disease patients, DR + IC counts were significantly increased in patients with advanced the cytoplasm compared with that of the nucleus was small. The cytoplasm had fewer inclusions and organelles than DC. The relative absence of organelles, the scanty cytoplasm, and the largely condensed chromatin in the nucleus suggested a more immature cell compared to DC ( Figure 4B ; DR + IC and EM). Given that the expression of HLA-DR and other costimulatory molecules such as CD40, CD80, CD83, or CD86 is known to reflect the maturation status of APC, we assessed their expression in DR + IC. As shown in Figure 4C , these cells revealed a low expression of CD80 (< 1%) and CD83 (< 1%), a moderate expression of CD86 (15%), and a high expression of CD40 (50%) and HLA-DR (100%). Notably, these data are consistent with an evaluation of CD40 expression in the blood DC compartment (encompassing DC and DR + IC) of 41 patients with breast cancer (stage I, n = 20; stage II, n = 12; and stage IV, n = 9). Patients with advanced disease had significantly increased CD40 expression (intensity and percentage; Figure 4D ) and concomitantly the largest proportion of circulating DR + IC (Figure 2A ).
disease (Figure 2B
). This is in keeping with the alteration in the percentage of DR + IC estimated as a proportion of the blood DC
Ability to Capture and Present Antigens to T-cells
The expression of HLA-DR and costimulatory molecules indicated a potential role of DR + IC as APC. To test this possibility, we set out to assess their capacity to capture and present antigen, and to induce T-cell activation. First, we studied the ability of DR + IC isolated from patients with breast cancer (stage II, n = 5) to capture a soluble antigen (FITC -TT). In fresh samples, DC had a higher capacity to take up antigens (DMFI: 61.2 ± 8.7) compared to DR + IC (DMFI: 9.4 ± 2.2) (P < .05; Figure 5A ). Given that DC are known to downregulate their capacity to capture antigens on activation [31] , we also assessed whether DR + IC could modulate their FITC -TT uptake in response to exogenous stimuli. Two classes of inflammatory mediators known to activate DC [29] were tested: 1) a combination of inflammatory cytokines (TNF-a, IL-1b, IL-6, and PGE 2 ; CC) [27] and 2) synthetic double-stranded RNA (poly I:C). We found that stimulated DC exhibited a small (not significant) reduction in antigen capture compared to unstimulated cells ( Figure 5B ). As with DC, DR + IC downregulated this capacity ( Figure 5B) , suggesting a certain level of functional modulation. We then assessed the ability of DR + IC to present antigens and to induce the proliferation of alloreactive T-cells. We found that DR + IC purified from patients with breast cancer (stage II, n = 5) induced a significantly reduced (P < .05) proliferation of allogeneic T-cells in MLR compared to DC ( Figure 5C ). Finally, we examined the capacity of DR + IC to induce IFN-g secretion in allogeneic T-cells. We found that DR + IC purified from cancer patients (stage II, n = 5) were poor stimulators of IFN-g secretion. Conversely, DC induced significantly (P < .001) higher levels of IFN-g secretion by T-cells ( Figure 5D ).
Response to Inflammatory Factors
Another feature of APC is their capacity to mature and respond to activation signals. As with antigen uptake, this ability is regulated by different types of inflammatory mediators [32] . Therefore, we assessed the phenotypic maturation of DR + IC and DC in response to a range of 1) proinflammatory mediators (CC) and 2) pathogen-derived factors, including ligands for toll-like receptors 4 (LPS), 3 (poly I:C), and 9 (bacterial oligodeoxynucleotide; CpG ODN)-all known to induce maturation of APC [27, 29, 32] . We analyzed 16 patients with breast cancer (stage II, n = 9; stage IV, n = 7) and found that freshly isolated DC were phenotypically immature, expressing low levels of CD40, CD80, CD83, and CD86 ( Figure 6 ). Similarly, DR + IC expressed low levels of CD80, CD83, and CD86, although, as noted previously, expression of CD40 was elevated in 40% to 50% of cells ( Figure 6 ). Interestingly, DR + IC responded weakly to inflammatory mediators and pathogen-derived products. Expression of HLA-DR (Table 1) and CD40 ( Figure 6, A -D) was increased, and a modest upregulation of CD83 and CD86 expression was noted in response to CpG ODN ( Figure 6D ) and occasionally to poly I:C ( Figure 6B ). In contrast, DC responded vigorously to all proinflammatory and pathogen-derived factors ( Figure 6 and Table 1 ), upregulating the expression of all costimulatory and activation markers (CD40, CD80, CD83, CD86, and HLA-DR).
Lineage Composition
Finally, given that DR + IC lacked an expression of markers associated with mature hematopoietic (CD3, CD14, CD19, CD20, and CD56) and circulating stem (CD34) cells, lineage composition of these cells was further evaluated (Table 2) . To obtain representative data, phenotypic analyses were conducted in a cohort of 21 patients with breast cancer (stage II, n = 17; stage IV, n = 4). It was found that variable proportions of DR + IC expressed molecules associated with DC [33] , including HLA-DR (100%), CD2 (7%), CD4 (3%), and CD1c (22%). Similarly, a consistent proportion of DR + IC expressed some early B-cell markers such as CD79a, SIgn, SIgE, and cytoplasmic Cm (14 -20%); and early progenitor markers such as CD7, CD10, CD13, CD33, and CD71 (3 -15%). Less than 5% of DR + IC expressed markers for the polymorphonuclear (PMN) or erythroid lineages such as MPO, CD15, or CD235a; and 5% to 30% expressed integrins such as CD11b, CD62L, CD41, and CD61. Altogether, these data suggested that multiple small subpopulations of immature cells ascribed to different lineages coexist within the DR + IC population.
Discussion
Despite the potential for tumor control, the immune system often fails to prevent cancer progression. Substantial evidence now indicates that defects in DC function have a crucial role in this process. Hence, research into the biology of DC tumor interactions has been the focus of much effort. Most knowledge in this field has emerged from in vitro studies whereby DC are generated from hematopoietic progenitors following culture with cytokines [14, 15, 34, 35] . However, cytokine-driven activity of cultured DC is unlikely to reflect the functional status of DC populations that are circulating in vivo. Therefore, despite inherent methodological constraints, we evaluated the blood DC compartment in a large cohort of patients with various types of cancer. We report that, in these patients, a population of HLA-DR + CD11c One intriguing aspect of these findings is how cancer progression could contribute to the selective accumulation of immature cells in the circulation. It may be related to 1) tumor-derived factors (granulocyte -macrophage colonystimulating factor) that promote the mobilization of precursors from the bone marrow [36] , or 2) tumor products (VEGF, IL-6, M-CSF, gangliosides, prostanoids, and spermine) that alter the differentiation of APC from their progenitors [12 -18] . Interestingly and supporting a role for tumor products in this process, we demonstrate a close correlation between accumulation of immature cells in the blood and It is also tempting to speculate that, although the systemic accumulation of immature cells could facilitate generalized immune dysfunction as a late event, immature APC present at the tumor site or lymphoid organs could play a role at an earlier phase in tumor progression. Indeed, in patients with head and neck squamous cell carcinoma, tumor infiltration with immature cells has been correlated with increased rate of recurrence and metastases [37] . In our hands, however, the direct identification of DR + IC in tumor stroma has remained difficult due to their lack of specific markers and Phenotypic maturation of DC and DR + IC was analyzed in PBMC following incubation with a combination of proinflammatory cytokines (TNF-a, IL-1b, IL-6, and PGE 2 ; CC) or pathogen-derived factors, including ligands for TLR4 (LPS), TLR3 (poly I:C), and TLR9 (CpG ODN). Data were collected from 16 patients with breast cancer (stage II, n = 9; stage IV, n = 7). The magnitude of the response is expressed as DMFI (MFI of stimulated cells À MFI of unstimulated cells) ± SEM. Statistically significant differences between DC and DR + IC are indicated. *P < .05. **P < .01. ***P < .001. heterogeneity (unpublished data). Nevertheless, purification and characterization of DR + IC were possible from the peripheral blood. Phenotypic characterization revealed minimal expression of CD80 and CD83, moderate levels of CD86, and high expression of CD40 and HLA-DR. Furthermore, 100% of DR + IC were MHC-I -positive, and 20% expressed CD1c. All these molecules are involved in APC -T-cell interactions, costimulation, and antigen presentation. Because these data suggested that DR + IC could potentially perform as APC, we assessed their capacity to 1) capture antigens, 2) stimulate T-cell proliferation/IFN-g secretion, and 3) mature in vitro on stimulation. Different types of stimuli or ''danger signals,'' including inflammatory cytokines, as well as ligands for toll-like receptors 4 (LPS), 3 (poly I:C), and 9 (CpG ODN), were tested. We found that, compared to DC, DR + IC had lower antigen capture, presentation, and phenotypic maturation in response to these inflammatory mediators. It may be suggested that this nonresponsiveness could be due to limited expression of cytokine or toll-like receptors. However, upregulation in HLA-DR and CD40 expression was evident with all stimuli (Table 1) . Similarly, elevated expression of CD83 and CD86 was noticeable in response to poly I:C and CpG ODN, suggesting that DR + IC could respond, at least to some extent, to inflammatory mediators. It may be that DR + IC are functionally impaired due to an effect of the tumor. In this regard, tumor-derived factors have been shown to induce abnormal intracellular signaling (STAT-3 and NFnB) in APC progenitors, thus hampering their differentiation and function [38, 39] . Alternatively, it could be related to the fact that most DR + IC are represented by immature cells at early stages of differentiation. The latter is more likely the case because stimulation with CD40 ligation induces DR + IC differentiation/ maturation, as shown in an accompanying paper. 1 We also confirmed the immaturity of DR + IC by morphology and phenotypic analyses. In contrast to DC, DR + IC were small cells with short projections, poorly developed organella, and largely condensed chromatin in the nucleus. Similarly, lineage characterization suggested that multiple subpopulations of immature cells were present. In accordance with these results, it has been reported that disease progression in cancer patients is associated with reduction of DC numbers and the appearance of a large number of immature macrophages, granulocytes, DC, and precursors of the myelo/ monocytic lineage in the peripheral blood [11, 36, 40] . Other studies indicate that accumulation of immature cells is not only an indicator for tumor progression but may also promote immune suppression. For instance, in patients with head and neck, lung, and breast cancers, immature cells have been shown to suppress responses to recall antigens and to inhibit antigen-specific immunity [40, 41] . In contrast to those studies, the DR + IC described here express HLA-DR and other molecules associated with antigen presentation (CD86, CD1c, and CD40), and capture and present antigens, suggesting a role as inefficient APC rather than cells with suppressive function. This assumption is further supported by the finding that DR + IC do not inhibit T-cell proliferation in either allogeneic or antigen-specific manner when competent DC are present, as described in our accompanying paper.
Interestingly, in contrast to the expression of HLA-DR, CD86, and CD1c, the expression of CD40 was significantly higher in DR + IC (51.0 ± 8.9%) when compared to DC (13.0 ± 5.5%). It has been demonstrated that CD40 ligation on DC increases their resistance to tumor-induced apoptosis [42] .
In an accompanying paper, we show that DR + IC's expression of CD40 renders them exquisitely sensitive to signaling through this pathway. Moreover, DR + IC demonstrate [21] . The findings reported here are relevant due to the large effort devoted to harnessing blood DC for the immunotherapy of cancer. In fact, blood DC have already been used for vaccination in patients with multiple myeloma, albeit demonstrating limited induction of tumor-specific immunity [43] .
Similarly, preclinical studies have demonstrated that, although DC generated in vitro from progenitors purified from cancer patients are capable of stimulating T-cell responses, blood DC isolated from the same patients are deficient in their APC capacity [8, 13] . Our study indicates that the defective function of circulating DC could, at least in part, be the result of decreased frequency of competent DC and accumulation of immature cells with poor APC function rather than suppressive function. As demonstrated in our accompanying paper (HLA-DR + Immature Cells Exhibit Reduced AntigenPresenting Cell Function But Respond to CD40 Stimulation), when T-cells primed with DR + IC were compared with T-cells primed with DC, a different activation ''pattern,'' as assessed by the expression of activation markers and cytokines, was noted. Indeed, a smaller proportion of T-cells expressed activation markers that were upregulated following adequate T-cell activation, and Th2 bias in cytokine secretion was detected. We propose that the significant accumulation of immature cells (DR + IC) with poor APC function could contribute to tumor immune evasion by displacing competent DC, presenting antigens inadequately and inducing Th2 bias, thus failing to generate effective antitumor responses. In summary, we document the significant accumulation of a novel population of cells within the blood DC compartment of patients with cancer. This population exhibits heterogeneous and immature phenotype, limited response to ''danger signals,'' and poor APC function. Increased numbers of these cells closely correlate with disease stage and tumor progression. It is possible that the accumulation of these cells could be associated with decreased immune function and compromised clinical status in patients with cancer. Our data should also be taken into account when assessing immune competence (i.e., DC enumeration/characterization in patients with cancer), and they necessitate prudence when using the peripheral blood DC compartment as a source of cells for DC-based cancer immunotherapy protocols.
